TolerogenixX GmbH
PrivateLast Round
Series A
Jul 6, 2023
Total Funding Raised
$12.63M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
TolerogenixX GmbH operates in Healthcare & Life Sciences and is based in Heidelberg. Its latest recorded funding round was a Series A round in July 2023.
TolerogenixX GmbH is a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TolerogenixX GmbH Comparables
Compare TolerogenixX GmbH with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Medeor Therapeutics | 85% | |
| Quell Therapeutics | 78% | |
| Cell4Cure AB | 75% |
For institutional investors. Book with your work email.
TolerogenixX GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 6, 2023 | ||||
| Seed | May 23, 2017 |
For institutional investors. Book with your work email.
TolerogenixX GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| High-Tech Gründerfonds | Series A, Seed |
| Kalodion | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 152% MoM, reaching 2.3K.
- Jul 24, 2026
Monthly visitors increased 77% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 11, 2026
TolerogenixX GmbH develops the Modified Immune Cells (MIC) platform to induce antigen-specific immune tolerance, with a Kidney International study providing preclinical proof-of-concept in lupus nephritis in Germany on Nov 11th '26.
For institutional investors. Book with your work email.
TolerogenixX GmbH Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TolerogenixX GmbH's valuation, stock price, and market status.
Is TolerogenixX GmbH a public or private company?
TolerogenixX GmbH is a private company.
What is the current stock price of TolerogenixX GmbH?
TolerogenixX GmbH is a private company, so its shares have no public market price. Caplight tracks TolerogenixX GmbH's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TolerogenixX GmbH worth (valuation)?
Valuation information for TolerogenixX GmbH is not publicly available.
Can I buy TolerogenixX GmbH stock?
TolerogenixX GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TolerogenixX GmbH's last funding round?
TolerogenixX GmbH's most recent funding round was Series A on July 6, 2023.
Who are the main investors in TolerogenixX GmbH?
Key investors in TolerogenixX GmbH include High-Tech Gründerfonds.
Will TolerogenixX GmbH IPO soon?
No public IPO plans have been announced for TolerogenixX GmbH.
How can I track TolerogenixX GmbH secondary market activity?
Caplight tracks bids, offers, and trades in TolerogenixX GmbH's shares on secondary markets.